Abstract

Neuronal network dysfunction is increasingly recognized as an early symptom in Alzheimer’s disease (AD) and may provide new entry points for diagnosis and intervention. Here, we show that amyloid-beta-induced hyperexcitability of hippocampal inhibitory parvalbumin (PV) interneurons importantly contributes to neuronal network dysfunction and memory impairment in APP/PS1 mice, a mouse model of increased amyloidosis. We demonstrate that hippocampal PV interneurons become hyperexcitable at ~16 weeks of age, when no changes are observed yet in the intrinsic properties of pyramidal cells. This hyperexcitable state of PV interneurons coincides with increased inhibitory transmission onto hippocampal pyramidal neurons and deficits in spatial learning and memory. We show that treatment aimed at preventing PV interneurons from becoming hyperexcitable is sufficient to restore PV interneuron properties to wild-type levels, reduce inhibitory input onto pyramidal cells, and rescue memory deficits in APP/PS1 mice. Importantly, we demonstrate that early intervention aimed at restoring PV interneuron activity has long-term beneficial effects on memory and hippocampal network activity, and reduces amyloid plaque deposition, a hallmark of AD pathology. Taken together, these findings suggest that early treatment of PV interneuron hyperactivity might be clinically relevant in preventing memory decline and delaying AD progression.

Highlights

  • Supplementary information The online version of this article contains supplementary material, which is available to authorized users.Alzheimer’s disease (AD) accounts for the most common form of dementia with a population prevalence that increases rapidly

  • APP/PS1 mice show hippocampal PV interneuron hyperexcitability at 15–17 weeks of age APP/PS1 transgenic mice were crossed with PV-Cre transgenic mice, generating an APP/PS1-PV-Cre mouse model that allows for the specific detection and genetic manipulation of PV interneurons in a progressive amyloidosis background

  • The amyloid cascade hypothesis has been leading in AD research over the past 30 years, it is still not clear how Aβ initiates AD-associated neuronal network dysfunction and cognitive impairment

Read more

Summary

Introduction

Recent clinical studies have described early prodromal AD stages that precede dementia, creating new opportunities for the development of novel treatment, and prevention strategies [1, 2]. Neuronal network dysfunction might be a risk factor for AD, a biomarker for identifying early stage AD or people at risk of developing AD, and a novel therapeutic entry point for effective treatment of AD [8,9,10,11]. Neuronal network alterations in AD have been identified as impairments in both excitatory and inhibitory synaptic transmission [4, 12]. Studies have focused on aberrant increases in excitatory neuronal activity, exploring the hypothesis that enhanced glutamatergic transmission is driving AD pathogenesis

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call